Latest Episodes
Ocugen Gene Therapy Shows Promise for Blindness
Phase 2 data shows 46% reduction in vision loss for geographic atrophy patients. Could this be the breakthrough millions have been waiting for?
Vaxart's Oral Vaccine Protects Babies Through Breast Milk
A pill that protects nursing infants through maternal antibodies. This could change global vaccine distribution.
New Duchenne Muscular Dystrophy Drug Approved in Switzerland
Santhera's AGAMREE receives 7th global approval with 15-year orphan drug exclusivity.
Biomerica's IBS Test Gets Medicare Coverage
Medicare establishes $300 national payment rate for inFoods IBS test. 40 million Americans could benefit.
Mainz Biomed Takes on Pancreatic Cancer Detection
AI-powered blood test aims to catch the 'silent killer' early. AACR presentation coming April 2026.
C4 Therapeutics Maps Road to 2028 Drug Approval
Cemsidomide Phase 2 on track with cash runway through 2028. A rare stability in biotech.
TG Therapeutics Projects 900 Million Dollar Year
BRIUMVI hit $594M in 2025. Targeting $875-900M in 2026. This is what biotech success looks like.
Nanobiotix's Radioenhancer Approach to Cancer
Nanoparticles that make radiation more effective without increasing the dose. Same treatment, better results.
Inotiv Advances Human-Relevant Drug Testing Models
TruVivo platform uses real human liver cells to predict drug toxicity. Closing the animal-to-human gap.
Evaxion Expands AI Platform to Autoimmune Diseases
One AI platform, three disease categories: cancer, infectious disease, and now autoimmune.